These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 27107096)

  • 1. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.
    Sy SK; Beaudoin ME; Zhuang L; Löblein KI; Lux C; Kissel M; Tremmel R; Frank C; Strasser S; Heuberger JA; Mulder MB; Schuck VJ; Derendorf H
    J Antimicrob Chemother; 2016 Jul; 71(7):1866-80. PubMed ID: 27107096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
    Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
    Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
    J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam-avibactam.
    Chauzy A; Buyck J; de Jonge BLM; Marchand S; Grégoire N; Couet W
    Clin Microbiol Infect; 2019 Apr; 25(4):515.e1-515.e4. PubMed ID: 30543853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.
    Li H; Estabrook M; Jacoby GA; Nichols WW; Testa RT; Bush K
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1789-93. PubMed ID: 25534728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.
    Biedenbach DJ; Kazmierczak K; Bouchillon SK; Sahm DF; Bradford PA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4239-48. PubMed ID: 25963984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
    Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
    Avery LM; Nicolau DP
    Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
    Livermore DM; Mushtaq S; Vickers A; Woodford N
    Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
    Le Terrier C; Nordmann P; Poirel L
    J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations.
    Sy SKB; Derendorf H
    Clin Microbiol Infect; 2018 Jul; 24(7):707-715. PubMed ID: 28760708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.
    Biagi M; Lamm D; Meyer K; Vialichka A; Jurkovic M; Patel S; Mendes RE; Bulman ZP; Wenzler E
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    Int J Antimicrob Agents; 2017 Feb; 49(2):239-242. PubMed ID: 27939093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.